393818-84-3

Upstream product

• 6831-55-6 2-(3,4-dichlorophenyl)acetyl chloride 
• 3162-96-7 4,6-O-benzylidene-1-O-methyl-α-D-glucopyranoside 
• 330953-54-3 (+)-[(2R,3S,6S)-2-cyanomethyl-6-methoxyoxan-3-yl] benzoate 
• 117468-12-9 (2R,4aR,6S,8aS)-(+)-6-methoxy-2-phenyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxine 
• 65530-27-0 (2R,4aR,6S,8aS)-(+)-6-methoxy-2-phenyl-4,4a,6,8a-tetrahydropyrano[3,2-d][1,3]dioxine 
• 18933-68-1 methyl 4-O-benzoyl-6-bromo-2,3,6-trideoxy-α-D-erythrohexopyranoside 

Downstream Products

• 393818-85-4 (+)-(2R,3S,6S)-2-{2-[2-(3,4-dichlorophenyl)acetylamino]ethyl}-6-methoxyoxan-3-yl 4-methylbenzenesulfonate 
• 393818-86-5 (+)-N-{2-[(2R,3R,6S)-3-azido-6-methoxyoxan-2-yl]ethyl}-2-(3,4-dichlorophenyl)acetamide 
• 393818-89-8 (+)-1-[(1R,5R,6R)-6-azido-9-oxa-2-azabicyclo[3.3.1]nonan-2-yl]-2-(3,4-dichlorophenyl)ethan-1-one 

Relevant academic research and scientific papers

Synthesis and opioid-receptor binding of novel amino-substituted morphan analogues

Starting with methyl 4,6-O-benzylidene-α-D-glucopyranoside (4), an optimized procedure is reported for preparation of the bromide 7, which is transformed into the N-acylated heptopyranosamine 9. After introduction of an axially positioned azido moiety in